| Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
|
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
| Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge |
|
BMJ Case Reports |
Myelodysplastic Syndromes (MDS) |
| MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia |
|
Blood Advances |
Aplastic Anemia |
| Modified Delphi panel consensus recommendations for management of severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
